[HTML][HTML] Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis
Y Zhou, Q Yang, J Chi, B Dong, W Lv, L Shen… - International Journal of …, 2020 - Elsevier
Y Zhou, Q Yang, J Chi, B Dong, W Lv, L Shen, Y Wang
International Journal of Infectious Diseases, 2020•ElsevierObjectives Existing findings regarding the relationship between comorbidities and the
severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim
of this study was to evaluate the association between different comorbidities and the severity
of COVID-19. Methods The PubMed, Embase, and Cochrane Library databases were
searched to identify studies reporting the rates of comorbidities in COVID-19 patients with
severe/fatal outcomes. Subgroup analyses were conducted according to disease severity …
severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim
of this study was to evaluate the association between different comorbidities and the severity
of COVID-19. Methods The PubMed, Embase, and Cochrane Library databases were
searched to identify studies reporting the rates of comorbidities in COVID-19 patients with
severe/fatal outcomes. Subgroup analyses were conducted according to disease severity …
Objectives
Existing findings regarding the relationship between comorbidities and the severity of coronavirus disease 2019 (COVID-19) are inconsistent and insufficient. The aim of this study was to evaluate the association between different comorbidities and the severity of COVID-19.
Methods
The PubMed, Embase, and Cochrane Library databases were searched to identify studies reporting the rates of comorbidities in COVID-19 patients with severe/fatal outcomes. Subgroup analyses were conducted according to disease severity and the country of residence. Odds ratios (OR) with 95% confidence intervals (CI) were pooled using random-effects models.
Results
A total of 34 eligible studies were identified. In patients with severe/fatal COVID-19, the most prevalent chronic comorbidities were obesity (42%, 95% CI 34–49%) and hypertension (40%, 95% CI 35–45%), followed by diabetes (17%, 95% CI 15–20%), cardiovascular disease (13%, 95% CI 11–15%), respiratory disease (8%, 95% CI 6–10%), cerebrovascular disease (6%, 95% CI 4–8%), malignancy (4%, 95% CI 3–6%), kidney disease (3%, 95% CI 2–4%), and liver disease (2%, 95% CI 1–3%). In order of the prediction, the pooled ORs of the comorbidities in patients with severe or fatal COVID-19 when compared to patients with non-severe/fatal COVID-19 were as follows: chronic respiratory disease, OR 3.56 (95% CI 2.87–4.41); hypertension, OR 3.17 (95% CI 2.46–4.08); cardiovascular disease, OR 3.13 (95% CI 2.65–3.70); kidney disease, OR 3.02 (95% CI 2.23–4.08); cerebrovascular disease, OR 2.74 (95% CI 1.59–4.74); malignancy, OR 2.73 (95% CI 1.73–4.21); diabetes, OR 2.63 (95% CI 2.08–3.33); and obesity, OR 1.72 (95% CI 1.04–2.85). No correlation was observed between liver disease and COVID-19 aggravation (OR 1.54, 95% CI 0.95–2.49).
Conclusions
Chronic comorbidities, including obesity, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, respiratory disease, kidney disease, and malignancy are clinical risk factors for a severe or fatal outcome associated with COVID-19, with obesity being the most prevalent and respiratory disease being the most strongly predictive. Knowledge of these risk factors could help clinicians better identify and manage the high-risk populations.
Elsevier
